Oxford Nanopore Technologies plc

Oxford Nanopore Technologies plc, founded in 2005 and originally known as Oxford NanoLabs Limited before its name change in May 2008, is a United Kingdom-based enterprise that specializes in developing and commercializing an innovative system for analyzing diverse molecular structures through nanopore-based sensing. Its product range features a variety of devices, including the portable MinION for sequencing deoxyribonucleic acid and ribonucleic acid, and the MinION Mk1C, which integrates basecalling, data analysis, touchscreen controls, and wireless connectivity. For benchtop operations, the company offers the GridION, capable of running and analyzing up to five MinION or Flongle flow cells, as well as the GridION Mk1 nanopore sequencer. High-yield sequencing is made accessible with the PromethION 2 Solo and PromethION 2, while the PromethION 24 and PromethION 48 provide benchtop nanopore sequencers for multiple users to achieve multi-sample and multi-experiment results. Further complementing these devices are Flongle, an adapter for MinION or GridION units, and VolTRAX, a USB-powered tool designed to automate laboratory processes preceding nanopore sequencing. The company also provides a suite of software solutions: MinKNOW facilitates data acquisition, real-time analysis and feedback, local basecalling, and data streaming; specialized Basecalling tools pinpoint the identity and sequence of bases on DNA/RNA molecules; EPI2ME is a cloud-based platform for comprehensive, real-time analysis of nanopore data; and EPI2ME Labs offers bioinformatics support to help users refine their skills and confidence in analyzing their sequencing data. Additionally, Oxford Nanopore Technologies is actively developing new products such as MinION Mk1D, Ubi, Plongle, and SmidgION. All of its products are available for purchase online.

Oxford Nanopore Technologies plc trades as ONT.L on LSE. The company is classified in Healthcare / Biotechnology and reports in GBP.

The current profile places the business in Biotechnology. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £223.90M of revenue and -£145.20M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Oxford Nanopore Technologies plc can be compared against peers such as 4basebio PLC, Avacta Group Plc, Fusion Antibodies plc, Faron Pharmaceuticals Oy, Genus plc, ImmuPharma plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £1.22B, beta of 0.91, and return on equity of -31.3%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

ONT.L currently shows total debt of £41.50M and beta of 0.91. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://nanoporetech.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.